PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
PMID: 39737899
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting. Urol Oncol. 2024 Nov 04.
PMID: 39500687
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879.
PMID: 39529961
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials.
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials. Cancer. 2025 Jan 01; 131(1):e35528.
PMID: 39192753
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22; 391(8):710-721.
PMID: 39167807
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials.
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials. Clin Cancer Res. 2024 Aug 01; 30(15):3098-3099.
PMID: 38767553
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
PMID: 38536082
Bladder-Preserving Trimodality Therapy With Capecitabine.
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
PMID: 38228414
Optimizing the doses of cancer drugs after usual dose finding.
Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
PMID: 38148731
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Prostate. 2024 Feb; 84(3):292-302.
PMID: 37964482
View All Publications